While private prescribing on a named-patient basis and supplying other companies will provide near-term revenues, getting approval for its THC oil as a treatment for chronic pain could be a game changer for Celadon. The study already had conditional approval from the Medicines and Healthcare products Regulatory Agency (MHRA), but couldn’t get started without the Ethics Committee’s decision. Recently the company said that it expects to activate its first supply deals before the end of the year. The approval has been granted to LVL Health, Celadon’s private pain clinic, on the strength of quality-of-life, pain and sleep data from the feasibility study, as well as evidence that subjects were able to reduce their use of opioid analgesics. Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK. The AIM-listed company said this morning that the NHS Research Ethics Committee had given the green light for the study in up to 5,000 non-cancer pain patients to get underway after it submitted the results of a three-month feasibility study.
Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK.
The AIM-listed company said this morning that the NHS Research Ethics Committee had given the green light for the study in up to 5,000 non-cancer pain patients to get underway after it submitted the results of a three-month feasibility study.
The approval has been granted to LVL Health, Celadon’s private pain clinic, on the strength of quality-of-life, pain and sleep data from the feasibility study, as well as evidence that subjects were able to reduce their use of opioid analgesics.
The...
Read the full article @ Cannabis Law Report